GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Accounts Payable

GENinCode (LSE:GENI) Accounts Payable : £0.61 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Accounts Payable?

GENinCode's Accounts Payable for the quarter that ended in Dec. 2024 was £0.61 Mil.

GENinCode's quarterly Accounts Payable increased from Dec. 2023 (£1.19 Mil) to Jun. 2024 (£1.38 Mil) but then declined from Jun. 2024 (£1.38 Mil) to Dec. 2024 (£0.61 Mil).

GENinCode's annual Accounts Payable declined from Dec. 2022 (£1.42 Mil) to Dec. 2023 (£1.19 Mil) and declined from Dec. 2023 (£1.19 Mil) to Dec. 2024 (£0.61 Mil).


GENinCode Accounts Payable Historical Data

The historical data trend for GENinCode's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Accounts Payable Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial 0.19 0.35 1.42 1.19 0.61

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.42 0.91 1.19 1.38 0.61

GENinCode Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


GENinCode Accounts Payable Related Terms

Thank you for viewing the detailed overview of GENinCode's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


GENinCode Business Description

Traded in Other Exchanges
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.